Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie

DRUG3 trials

Sponsors

Iovance Biotherapeutics Inc., Stichting Radboud universitair medisch centrum

Conditions

MDS with excess blastsMDS/AML or AML patientsMelanomaMetastatic Non-Small-Cell Lung Cancer

Phase 2

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

RecruitingCTIS2024-510778-26-00

Iovance Biotherapeutics Inc.Metastatic Non-Small-Cell Lung Cancer

Start: 2025-12-19Target: 115Updated: 2025-11-26

NK4AML: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study

Not yet recruitingCTIS2024-515357-16-00

Stichting Radboud universitair medisch centrumMDS/AML or AML patients, MDS with excess blasts

Target: 16Updated: 2025-01-20

Phase 3

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma

RecruitingCTIS2022-503140-41-00

Iovance Biotherapeutics Inc.Melanoma

Start: 2024-11-29Target: 280Updated: 2025-10-31